Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 13 Issue 5, December 2019

Volume 13 Issue 5

In this issue...

• A review of the biopharma deals of 2019

• Partnering with the complement cascade

Cover image: Test tubes filled with pills and dollars. Core Imagery / Alamy Stock Photo.

A review of the biopharma deals of 2019

    Feature

  • News Feature |

    2019 has seen a boom in high-value M&A and licensing deals, with oncology and rare diseases as prominent themes.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    By harvesting stem cells from umbilical cord blood and differentiating them into natural killer cells, Glycostem has developed oNKord, an affordable off-the-shelf cell therapy product indicated for oncology therapies that is ready to ship worldwide within 48 hours.

    • Glycostem
  • Advertisement Feature |

    enGene has developed a proprietary nonviral gene delivery platform and Gene Pill technology to deliver orally administered gene therapies to mucosal tissues, creating new opportunities for treating hard-to-reach tissues across many indications.

    • enGene

Partnering with the complement cascade

    Feature

  • News Feature |

    The complement pathway’s intricate network of proteins, which have a key role in the innate immune system, are attracting dealmakers’ attention as targets for a variety of inflammatory diseases.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    Noveome Biotherapeutics, Inc. is developing a new class of biologic consisting of the secretome of a novel population of cells derived from the amnion. Presently, the company is looking for partners to drive clinical drug development of its lead product, ST266, in ophthalmological indications.

    • Noveome Biotherapeutics
  • Advertisement Feature |

    With its lead candidate, ATH3G10, a first-in-class antibody indicated for large ST-elevation myocardial infarction (STEMI), Athera Biotechnologies is harnessing the process of efferocytosis to treat a range of vascular diseases.

    • Athera Biotechnologies AB

Search

Quick links